Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic Dermatitis

Eric L. Simpson, Marjolein de Bruin-Weller, Ashish Bansal, Zhen Chen, Lauren Nelson, Diane Whalley, Randy Prescilla, Isabelle Guillemin, Dimittri Delevry

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The Patient-Oriented Eczema Measure (POEM) assesses patient-reported severity of atopic dermatitis (AD) symptoms, whereas the Children’s Dermatology Life Quality Index (CDLQI) measures how AD affects health-related quality of life (HRQoL) in children. Although the POEM and CDLQI have established thresholds for clinically meaningful within-patient change in adolescents (aged 12–17 years), there are no defined within-patient responder thresholds for clinically meaningful change in children aged 6–11 years. Methods: Data from the LIBERTY AD PEDS phase 3 randomized, double-blind, placebo-controlled trial of dupilumab in children aged 6–11 years with severe AD were used to define the threshold for within-patient meaningful change in POEM and CDLQI scores. Anchor-based methods were applied to estimate mean change in POEM and CDLQI scores from baseline to week 16, with anchors of a 1-point improvement in the Patient Global Impression of Disease (PGID) scale and an improvement in score of ‘‘A little better’’ on the Patient Global Impression of Change (PGIC) scale. The distribution-based methods, a one-half standard deviation (SD) at baseline and a standard error mean (SEM) were also used. Results: The mean POEM change scores associated with the anchors were a change of − 8.40 with the PGID anchor and − 6.30 with the PGIC anchor. Distribution-based estimates for POEM were one-half SD at baseline of 2.76, with a SEM of 3.32. Mean CDLQI change scores corresponding to the PGID and PGIC anchors were − 7.30 and − 6.80, respectively, while distribution-based estimates for CDLQI were a one-half SD at baseline of 3.69, with a SEM of 3.52. Conclusions: In children with severe AD, an appropriate minimum threshold of clinically meaningful within-patient change was estimated as 6 points for both the POEM and CDLQI scores. Trial registration: ClinicalTrials.gov Identifier: NCT03345914. [MediaObject not available: see fulltext.]

Original languageEnglish (US)
Pages (from-to)1415-1422
Number of pages8
JournalDermatology and Therapy
Volume11
Issue number4
DOIs
StatePublished - Aug 2021

Keywords

  • Atopic dermatitis
  • CDLQI
  • Clinically meaningful
  • Dupilumab
  • POEM
  • Pediatric
  • Psychometric
  • Responder threshold
  • Validation

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic Dermatitis'. Together they form a unique fingerprint.

Cite this